文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

立体定向MR引导自适应再程放疗用于局部复发前列腺癌

Salvage stereotactic MR-Guided adaptive radiotherapy (SMART) re-irradiation for locally recurrent prostate Cancer: Clinical and dosimetric outcomes.
PubMed 文献 · Clin Transl Radiat Oncol · 2025-08-26

本文回顾性分析19例局部复发前列腺癌患者接受每日SMART再程放疗(30-35 Gy/5次)的安全性与疗效,中位随访21个月。结果显示OS 100%、bRFS 73.7%、LC 84.2%,急性2级GU毒性21%,晚期3级GU毒性15.7%,无急性≥3级GU或≥2级GI毒性,提示该方案可行且毒性可控。

要点

  • 每日SMART再程放疗对局部复发前列腺癌可行,局部控制率高。
  • 急性2级GU毒性21%,晚期3级GU毒性15.7%,无严重GI毒性。
  • EQD2累积剂量计算可用于再程放疗OAR约束评估。

核心结论

  • 每日自适应SMART再程放疗是局部复发前列腺癌可行、无创的挽救治疗选择,局部控制率高且毒性低。
  • 经验支持将MR引导与个体化EQD2指导的计划设计相结合。

研究设计与样本

  • 回顾性分析2019至2023年19例组织学证实的非转移性激素敏感性局部复发前列腺癌患者。
  • 纳入标准包括首程放疗后≥18个月、PSA≤30 ng/mL、PSA倍增时间>6个月、IPSS≤19、前列腺≤80 cc及cT1-T3a/b。
  • 再程方案为30-35 Gy/5次,允许剂量提升和激素治疗,推荐直肠间隔物。

主要发现

  • 再程放疗距首程中位87个月(范围35-587),靶区为全腺体12例、半腺体5例、精囊2例。
  • 全部95次分次均行在线自适应,满足所有预估OAR约束。
  • 中位随访21个月,急性2级GU毒性21%,未观察到急性≥3级GU或≥2级GI毒性。
  • 晚期3级GU毒性见于3例(15.7%)。
  • OS 100%,bRFS 73.7%,LC 84.2%,中位PFS未达到,1年和2年PFS分别为94.7%和89.4%,1年和2年LC均为100%。

关键数值与推荐

  • 再程放疗剂量30-35 Gy/5次。
  • 纳入PSA≤30 ng/mL、PSA倍增时间>6个月、IPSS≤19、前列腺≤80 cc。
  • 半腺体治疗后观察到2例对侧前列腺内失败。

临床怎么用

  • 对符合条件的局部复发前列腺癌患者,可考虑每日SMART再程放疗作为挽救选项。
  • 治疗中应利用每日在线自适应和实时追踪保护OAR。
  • 建议使用EQD2方法累积评估OAR剂量以指导再程放疗计划。

局限性

  • 回顾性分析,样本量仅19例。
  • 中位随访21个月,晚期毒性及疗效需更长期随访。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Stereotactic ablative radiotherapy (SABR) is a salvage option for locally recurrent prostate cancer (LRPC); however, challenges remain. Stereotactic MRguided Adaptive Radiotherapy (SMART) permits daily adaptation, real-time tracking and automated beam gating, allowing critical organ sparing while potentially improving target coverage. Equivalent Dose in 2 Gy fraction (EQD2) calculation allows accurate organs-at-risk (OAR) dose accumulation in re-irradiation.We report safety and efficacy of daily SMART re-irradiation for LRPC, alongside an EQD2-based OAR tolerance calculation method. METHODS: Salvage SMART to histologically proven non-metastatic hormone-sensitive LRPC was retrospectively analysed. Inclusion criteria included: ≥18 months post-RT, prostate-specific antigen (PSA) ≤ 30 ng/mL, PSA doubling-time > 6 months, International Prostate Symptom Score (IPSS) ≤ 19, prostate ≤ 80 cc and cT1-T3a/b.Reirradiation regimens were 30-35 Gy/5 fractions. Dose-boost and hormone therapy were allowed. Rectal spacer was recommended.Outcomes included toxicity, local control (LC), biochemical relapse-free survival (bRFS), progression free survival (PFS) and overall survival (OS). EQD2-based workflow to estimate OAR cumulative constraints was reported. RESULTS: Between 2019 and 2023, nineteen patients underwent salvage-SMART to whole-gland (n = 12), hemi-gland (n = 5) or seminal vesicle (n = 2) at a median 87 months (range 35-587) from first radiotherapy. All 95 delivered fractions underwent online adaptation, meeting all estimated OAR.With 21 months follow-up, acute grade 2 genitourinary (GU) toxicity was 21 % with no acute ≥ grade 3 GU or ≥ grade 2 gastrointestinal (GI) toxicity observed. Late GU grade 3 toxicity occurred in 3 patients (15.7 %).OS was 100%; bRFS 73.7%; LC 84.2%; and median-PFS was not reached. One and two-year PFS were 94.7% and 89.4%. One and two-year LC was 100%. Two contralateral intraprostatic failures followed hemi-gland treatment were observed. CONCLUSION: Daily adaptive SMART re-irradiation is a feasible, non-invasive salvage option for LRPC, combining high LC with low toxicity. Our experience supports integrating MR- guidance with an individualized EQD2-informed planning.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Moreno-Olmedo E, Murray D, George B, et al. Salvage stereotactic MR-Guided adaptive radiotherapy (SMART) re-irradiation for locally recurrent prostate Cancer: Clinical and dosimetric outcomes. Clin Transl Radiat Oncol. 2025. PMID: 41536761. doi:10.1016/j.ctro.2025.101037

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。